INTRODUCTION
============

The recent passing of David Hubel (September 22, 2013) occurs in the midst of a rich era of research into the activity-dependent (A-D) formation and refinement of neural circuitry during normal brain development and in neurodevelopmental disease states. Hubel and Wiesel's pioneering studies on monocular deprivation and activity manipulations in the cat visual system ([@B189], [@B190], [@B191]; [@B415]) laid the foundation for our understanding of the A-D assembly and pruning of synaptic connections. All synapses formed through the reciprocal, highly orchestrated crosstalk between axons and dendrites face the bottleneck decision of elimination versus long-term maintenance and strengthening to form a stable partnership (dendrite stabilization review, [@B224]; intrinsic dendrite development, [@B332]). Although early synaptogenesis proceeds via largely activity-independent mechanisms, the refinement of synapses is a progressive, A-D process most active during the early-use critical periods of postnatal development, when synaptic arrays are most amenable to pruning and *de nova* additions ([@B178]). Following this refinement period, A-D modulation is greatly reduced in the mature brain, except for maintenance of the synaptic plasticity underlying behavioral adaptation ([@B340]; rodent visual cortex, [@B294]). Recent advances in biotechnology provide high-fidelity readouts of neural activity, as well as precise, non-invasive methods for the bidirectional manipulation of neural activity ([@B66]; [@B250]), generating the means to study A-D developmental processes at a previously inconceivable level.

Autism spectrum disorders (ASDs) are defined by social interaction impairments ([@B1]), frequently accompanied by sensory hypersensitivity, cognitive deficits, and A-D seizures ([@B221]; [@B218]). The improper development of neural circuitry likely lies at the heart of ASDs, particularly the A-D processes of solidifying appropriate synaptic connections and concomitantly pruning superfluous or incorrect connections ([@B441]). The apparently diverse genetic bases of the wide spectrum of autism-related disorders makes genetic modeling a challenge ([@B349]), but recent hypotheses suggest that the variety of genetic variants associated with ASDs may converge on a more manageable set of core molecular pathways ([@B287]). With this in mind, targeted mouse and *Drosophila* animal model systems harboring deficiencies in ASD-linked human genes often show comparable phenotypic and behavioral defects to human patients ([@B168]; [@B395]). Among the strongest primary research contributions have come from models of fragile X syndrome (FXS), a monogenic disorder that is the leading heritable contributor to the autism spectrum ([@B171]; [@B270]). In both mouse and *Drosophila* FXS models, there is clear and consistent evidence that the causal fragile X mental retardation protein (FMRP) is directly activity-regulated and in turn regulates A-D processes of neural circuit assembly and refinement ([@B402],[@B403]; [@B420]). Preclinical studies with these animal models have already advanced to a number of human clinical trials \[e.g., metabotropic glutamate receptor (mGluR) therapeutics\], and groundbreaking tools to assess and manipulate A-D synapse and circuit development show great promise toward major breakthroughs in ASD therapeutic intervention strategies ([@B3]; [@B317]; [@B374]).

In this review article, we seek to highlight recent advances in our understanding of A-D synaptic development in the normal and ASD brain, particularly focused on recent work from mouse and *Drosophila* genetic models. We will only mention is passing electrophysiological investigations of synaptic plasticity at maturity, which is the focus of many excellent reviews ([@B261]; [@B296]; [@B59]). Likewise, the broad genetic and molecular details of A-D neural circuit assembly have recently been presented elsewhere ([@B134]; [@B411]; [@B114]). Our main focus will be on the A-D basis of ASDs, and particularly on FXS, as the leading heritable contributor to this neurodevelopmental disease condition ([@B169]). Starting with a brief review of normal experience-dependent synaptic changes (Part 1), we will then focus on correlates between the ASD disease state and A-D circuit formation (Part 2), and finally finish with a detailed review of the recent technological advances for the manipulation and monitoring of A-D processes (Part 3) during neural circuit development.

PART 1: NORMAL ACTIVITY-DEPENDENT NEURODEVELOPMENT
==================================================

[@B175] theorized that neural activity would code neural circuit connectivity through a mechanism of coincident synapse elimination and consolidation. This theory was first tested in the cat visual cortex, with the first visual response recordings made in the 1950s ([@B39], [@B40], [@B41]; [@B75]; [@B208]), coincident with the pioneering work of [@B236] defining ganglion cell specificity/organization and producing some of the first primary evidence of higher order processing. Kuffler's students went on to establish the principles of A-D mechanisms (**Figure [1A](#F1){ref-type="fig"}**), including Horace Barlow's characterization of selectivity and lateral inhibition in the frog retina ([@B18],[@B19]), and David Hubel and Torsten Wiesel's work on the basis of A-D (and later experience-dependent) synaptic development in the cat retinal system. Hubel and Wiesel first demonstrated that individual striatal cortical neurons (primary visual cortex) respond preferentially to slits of light ([@B189]), providing a mechanism by which cortex organization enables higher order perception ([@B190]). Their subsequent studies using monocular deprivation revealed profound changes in cortex development, with active-pathway axons from the lateral geniculate nucleus (LGN) dramatically out-competing inactive axons for cortex innervation of striatal cortical neurons ([@B415]). The LGN innervated by the monocularly deprived retinal axons was also thinner, demonstrating a sensory experience-dependent restructuring of the developing neural circuit ([@B415]).

![**Activity-dependent synaptic remodeling during critical periods.** **(A)** Progression of dendrite development. Highly dynamic dendrites occur in the A-D critical period prior to consolidation of relatively stable mature connections ([@B233]). **(B)** Synapse number changes as a function of age. Defects in synaptogenesis (formation, pruning, and stabilization) correlate with onset of specific neurological disorder classes, including intellectual disability (1), ASDs (2), schizophrenia (3), and Alzheimer's disease (4) (for example, [@B320]). **(C)** Activity-dependent synapse changes occur during the critical period, in which synaptic partnerships are solidified or dissolved prior to consolidation, coinciding with inhibitory interneuron innervation, progressive myelination and the formation of extracellular perineuronal nets ([@B177]).](fncel-08-00030-g001){#F1}

Hubel and Wiesel went on to perform an extended series of A-D developmental studies, establishing a critical period for visual cortical development in kittens, and demonstrating that adult cats show no comparable experience-dependent morphological or electrophysiological changes ([@B415], [@B416],[@B417]; [@B191]; [@B414]; [@B79]). Following these pioneering studies, A-D morphological changes were similarly revealed in other areas of the sensory cortex. As one example, upon trimming whiskers in specific rows, axonal projections in the rat somatosensory cortex were reduced from non-deprived columns into deprived columns (axons from column A generally innervate column B; if the B column is deprived of input, the A axon receives no postsynaptic response and collapses), and increased horizontal axonal projections between non-deprived columns ([@B54]). Whisker trimming on the rat's snout from birth leads to a smaller contralateral motor area that evokes abnormal motor activity, a phenomenon not seen in adult rats ([@B193]), again indicating a transient developmental window. Neuromuscular junction (NMJ) innervation is another classic system for studying A-D remodeling ([@B355]). Motor axons compete to target individual muscle fibers during the early-use neonatal period ([@B350]), and NMJ development in the first couple of neonatal weeks displays a progression of A-D synapse elimination, functional reinforcement, and eventual structural consolidation ([@B248]; [@B401]). Consistently, impeding neural activity results in slowed synaptic refinement in the mouse neuromusculature, and enhancing activity increases the rate of development ([@B384]).

Humans show similar mechanisms of A-D neural circuit development (**Figure [1B](#F1){ref-type="fig"}**). For example, the auditory cortex displays an early age critical window of experience-dependent maturation, with professional musicians developing asymmetric brain features when exposed to music before the age of 7. Specifically, development of absolute pitch correlates with a larger left planum temporale ([@B353]), and enlarged cortical representation of the left hand in dexterous string players ([@B115]; [@B353]). Auditory cortical development may actually represent a more extensive (or indefinite) critical period, as compared to other sensory modalities ([@B216]; [@B62]). This relative extension may result from a late peak of parvalbumin-expressing (PV+) interneurons, as described in ferret brain development ([@B145]). The emergence of these inhibitory interneurons is progressive ([@B186]) and vital for the proper formation of cortical circuits (**Figure [1C](#F1){ref-type="fig"}**; [@B328]). The auditory critical period is not open ended, however, as childhood ear infections leading to long-term deficits in auditory perceptual acuity can occur if not treated before the age of 7 ([@B326]). These select examples illustrate normal A-D development within single sensory modalities. ASD symptoms may manifest through faulty A-D development in a number of sensory systems, with impairments of higher-order cognition circuitry developing after formation of primary sensory circuitry ([@B27]; [@B150]). Although ASD diagnoses focuses on higher order cognitive tasks such as social communication, language and cognitive development, and repetitive behaviors ([@B443]), precursor deficits in primary sensory processing are characteristic ([@B265]). A more detailed discussion of ASD phenotypes is presented in Part 2.

CRITICAL PERIODS OF NEURAL CIRCUIT DEVELOPMENT
----------------------------------------------

The highly dynamic nature of synaptic connectivity is largely a transient feature of neurodevelopment: long-term imaging of dendritic spines in adult mice reveals that most mature synapses are relatively stable ([@B166]). The critical window (or critical period) theory has emerged to explain the decline in synaptic dynamics as the brain develops, and as a mechanistic foundation toward understanding ASD disease states (**Figure [1](#F1){ref-type="fig"}**; [@B178]). A critical period defines a temporary developmental window of heightened sensitivity to sensory stimuli, which drive connectivity changes ([@B182]), with A-D modulation reduced after the window passes, as reflected by the decrease in spine turnover as the brain matures ([@B387]; [@B184]; [@B442]). The key critical period hallmarks include (1) competition between circuit elements, (2) neural activity regulation, (3) structural solidification of maintained connections, (4) sharply-defined experience-dependent window, (5) variable/hierarchical timing and duration of windows across systems, (6) a diversity of molecular mechanisms underlying A-D modulation, (7) emergence and connectivity of inhibitory neurons, (8) attention/motivation by aminergic and cholinergic modulation, and (9) the potential for reactivation in adulthood (**Figure [1](#F1){ref-type="fig"}**; [@B178]). Synaptogenesis underlies these hallmarks in critical periods, and takes place sequentially through initial axonal/dendritic outgrowth, excess formation of synapses, and subsequent pruning through A-D maturation ([@B211]; [@B411]). Although synapse regulation continues throughout life ([@B184]; [@B165]), peak synaptogenesis occurs during early postnatal life ([@B309]).

The terminal periods of critical windows coincide with other hallmarks of neurodevelopment (**Figure [1C](#F1){ref-type="fig"}**). These include the progressive myelination of nerve fibers, which is a process essential for cortical function; mice caged in isolation 2 weeks after weaning show reduced myelin and diminished cortical function ([@B260]). Importantly, myelination is also delayed in FXS ([@B305]). Also relevant to ASD disease states is the emergence and maturation of local inhibitory (I) interneurons coincident with the end of critical periods, to provide balance to young excitatory (E) circuits (**Figure [1C](#F1){ref-type="fig"}**; [@B178], [@B179]). The correct development of E/I ratio is critical to neural circuit output, and defects in the E/I ratio balance is a leading candidate mechanism for explaining the emergence of ASD disease states ([@B148]). Both hyperexcitation and hypoinhibition are recurring themes in numerous ASD models ([@B58]). More generally, genetic disruption of cortical interneuron development causes regional GABAergic deficits, epilepsy and ASD-like behavioral changes in mice ([@B327]). As one example, mice deficient for the axon guidance receptor *neuropilin 2* display reduced cortical interneuron numbers and are more prone to seizure following neuronal excitation ([@B142]). Thus, the critical period theory must include the temporally phased regulation of first excitatory and then inhibitory synapses, such that A-D synapse selection generates the appropriate E/I synapse ratio balance. There are other hallmarks of critical period cessation, including the A-D establishment of the perineuronal network, a matrix of chondroitin sulfate proteoglycans (**Figure [1C](#F1){ref-type="fig"}**; [@B426]). Roles of glycan modifications in ASD models will be further discussed below in Part 2.

ACTIVITY-DEPENDENT SYNAPSE MECHANISMS IN *Drosophila*
-----------------------------------------------------

Synaptic ultrastructure and function is remarkably conserved across species, for example, comparing mammalian brain glutamatergic synapses to *Drosophila* NMJ glutamatergic synapses ([@B355]). Moreover, the underlying molecular elements of synapses are similarly extremely well conserved, allowing mutually complementary studies in animals ranging from rodents to flies ([@B127]; [@B223]). Most A-D work in *Drosophila* has focused on axonal (presynaptic) development ([@B344]), whereas most comparable work in mouse has focused on dendritic (postsynaptic) spines. However, the *Drosophila* NMJ postsynaptic domain is well described and clearly subject to extensive A-D remodeling. It contains two functional classes of ionotropic glutamate receptors (iGluRs; [@B268]) and a single metabotropic glutamate receptor (DmGluRA; [@B45]). Postsynaptically, iGluRs are trafficked and stabilized downstream of A-D mechanisms ([@B383]), and *in vivo* imaging has shown that presynaptic release of dense core vesicles is A-D, with potentiation of release dependent on Ca^2+^ influx and CaMKII (Ca^2+^/calmodulin-dependent protein kinase II) activation ([@B357]). DmGluRA nulls show increased A-D facilitation and decreased synaptic boutons of increased size, suggesting the receptor acts as an activity monitor controlling both synapse function and structure ([@B45]). DmGluRA loss leads to increased expression of iGluRs, and DmGluRA over-expression leads to decreased iGluRs ([@B310]), demonstrating a tight regulation of postsynaptic receptor composition as an activity response mechanism. These A-D processes in the postsynaptic domain are directly impacted in the *Drosophila* FXS disease model as discussed below in Part 2.

The *Drosophila*NMJ is a particularly dynamic synaptic structure during early development, with A-D growth modulated during larval crawling behavior and mediated via glutamatergic neurotransmission ([@B355]). Live imaging shows NMJ growth proceeds by a variety of mechanisms: stretching of existing boutons and insertion of new boutons in between, adding new boutons to the end of an existing strand, *de novo* addition and branch formation from existing boutons ([@B439]). A crude method to increase NMJ transmission is through chronic rearing at 29--30°C, which results in accelerated synapse growth ([@B363]; [@B436]). Spaced depolarization via high K^+^ saline application leads to the rapid extension and retraction of short filopodia, and the formation of synaptic boutons ([@B10]). Reduced membrane excitability via inward current mutants (*paralytic* Na^+^ channel) or other Na^+^ channel loss-of-function (*tipE* or *mle*^nap-ts1^) leads to improper synaptic refinement ([@B201]; [@B413]), with significantly smaller synaptic boutons ([@B255]). Acute depolarization of the NMJ leads to the formation of "ghost boutons," that initially lack presynaptic active zones and postsynaptic iGluRs, which appear on a timescale of hours ([@B10], [@B11]). Generation of genetically targetable channels, such as the voltage-dependent UAS-EKO and UAS-Kir2.1 ([@B15]; [@B312]), and the constitutively open UAS-dORK potassium channel shunt ([@B413]) allow a more precise dissection of the effects of activity regulating NMJ synaptic morphology. Recent advances in bioengineering have taken advantage of channel variants for genetically targeted hyperexcitation in *Drosophila*, including the *transient receptor potential* (TrpA1; [@B170]) and TrpM8 thermogenic channels ([@B318]), the constitutively active NaChBac channel ([@B299]), the expanding family of channelrhodopsin (ChR2) variants ([@B354]; [@B11]), and the hyperpolarizing eNpHR3.0 channel ([@B195]). These new methods will be more fully described below in Part 3.

Beyond neurotransmission *per se*, proper formation of the *Drosophila* NMJ entails other A-D *trans*-synaptic signaling mechanisms. Wnt signaling via wingless (Wg; [@B306]; [@B227]) functions downstream of activity (high K^+^ depolarization, ChR stimulation) to regulate both structural and functional development ([@B11]; [@B226]). Similarly in mammals, activity regulates *Wnt2* transcription, which stimulates dendritic arborization in hippocampal cultures ([@B409]). Bone morphogenetic protein (BMP) signaling via glass bottom boat (Gbb; [@B272]; [@B215]) leads to NMJ stabilization through LIM kinase 1 activity, preventing retraction and synapse loss ([@B113]). Recent use of *Shaker* K^+^ channel mutants (or raising temperature to 30°C) to increase excitability, shows that retrograde BMP signaling is required for A-D NMJ growth and maturation ([@B30]). Heparan sulfate proteoglycan (HSPG) co-receptors of such signaling ligands ([@B338]), including Dally-like protein (Dlp) and Syndecan (Sdc), play important roles in NMJ synaptogenesis ([@B204]; [@B92]). Importantly, HSPGs interact closely with FMRP to modulate *trans*-synaptic signaling in the *Drosophila* FXS disease model ([@B136]), suggesting a link to A-D processes. Laminin A (LanA) is another extracellular synaptic protein of interest that is downregulated in response to activity to regulate synaptic architecture: LanA expression is inversely correlated with NMJ size, and is regulated by larval crawling activity, synapse excitation, postsynaptic response, and Wnt signaling ([@B389]). These A-D processes in the presynaptic domain are directly impacted in the *Drosophila* FXS disease model as discussed below in Part 2.

Although A-D development has been explored at length at the *Drosophila* NMJ, more limited studies have examined A-D mechanisms in the brain, mainly focusing on the mushroom body (MB) learning and memory center ([@B432]; [@B266]). These studies have been enhanced by recent generation of more targeted Gal4 drivers and new optogenetic tools allowing cell-autonomous, single-cell resolution dissection of A-D mechanisms in normal and disease states ([@B67]). Using the mosaic analysis with a repressible cell marker (MARCM) clonal technique ([@B240]), characterization of MB axons shows critical period development at the level of individual cells: synaptic branches display significant A-D pruning during the early-use period following eclosion, but become relatively static at maturity ([@B378]). Importantly, sensory deprivation (SD) elevated synaptic branch number during this critical period, whereas activity depolarization of single-cell MARCM clones by ChR2 optical stimulation significant decreased synaptic branching during this same critical period ([@B378]). Similarly, recent work silencing olfactory sensory neurons (via UAS-Kir2.1; Limb3b-Gal4 or UAS-DorK; Limb3b) lead to immature axonal morphology, including broad axon terminals and multiple filopodia ([@B329]). Silencing of a limited subset of projection neurons innervating the MB (UAS-dORK1.deltaC; Mz19-Gal4) leads to increased size, number, and active zone density of axon terminals within the microglumeruli of the MB calyx ([@B232]). These A-D processes in the brain MB learning/memory center are directly impacted in the *Drosophila* FXS disease model, as discussed below in Part 2.

Information on A-D mechanisms regulating dendrites in the *Drosophila* genetic model is more limited, but this research focus is rapidly expanding. For example, motor neuron dendrite structural development has been shown to be regulated downstream of high K^+^ depolarization ([@B172]; [@B444]). Moreover, a role for synaptic activity in dendritic remodeling has been shown via targeted transgenic tetanus toxin expression (UAS-TNT; [@B375]) blocking neurotransmitter release from cholinergic interneurons (Cha-Gal4; UAS-TNT) leads to increased dendritic structural complexity ([@B388]). Dendritic refinement in serotonergic neuron pupal development is also modulated by activity: hyperpolarization via UAS-Kir2.1 caused increased dendritic length, which was proposed to be due to A-D Wnt/Wg signaling with a pro-retraction role in sensory-input dendritic refinement ([@B366]). Similarly, the silencing of olfactory sensory neurons (via UAS-Kir2.1; Orco-Gal4) led to enhanced dendritic occupancy of the antennal lobe by projection neurons ([@B329]). However, it is also clear that A-D differences may be found across different neuronal types or developmental stages. For example, increased firing of RP2 motor neurons caused by dominant negative *Shaker*and *eag* K^+^ channel mutations resulted in increased dendritic complexity, whereas Kir2.1 silencing resulted in decreased dendritic structure ([@B385]). Moreover, constitutively active CaMKII also led to increased dendrite length and branching ([@B385]). Use of the temperature-gated TrpA1 channel to activate neuron firing demonstrated that MN5 flight motor neuron dendrites respond to activity differently over time: increased activity before pupal day 6 caused decreased dendritic branching ([@B400]), whereas increased activity later in development caused increased branching ([@B110]), again suggesting differential A-D critical periods.

Mammalian models of dendritogenesis display similar A-D mechanisms to those characterized above in *Drosophila*. For example, increased neural activity and glutamatergic signaling led to dendritic spine outgrowth ([@B206]; [@B9]), and spine turnover rates in young mice were shown to be sensory experience-dependent ([@B387]). Long-term SD through whisker trimming led to dendritic spine pruning that was more prominent in young mice ([@B442]), and spine synapse densities changed upon rearing or training in enriched environments ([@B162]; [@B26]; [@B284]). Spaced depolarization of hippocampal neurons in culture led to extension of new spines, a process correlated with A-D MAPK activation ([@B423]). Recent advances in live imaging have elegantly provided *in vivo* evidence of A-D dendritic spine dynamics ([@B5]; [@B182]). As one example, the immediate early gene Arc/Arg3.1 functions to eliminate surplus climbing fibers (CF) onto Purkinje cell synapses in the cerebellum, a process that is accelerated with ChR2 depolarizing stimulation for 2 days and suppressed by targeted CF knockdown of voltage-gated Ca^2+^ channels ([@B278]). Limited regions of the adult brain remain amenable to similar changes, for example, hippocampal spine density increased in adult rats following spatial learning ([@B284]), and multiphoton imaging of dendritic spines during mGluR-induced long-term depression (LTD) showed spine shrinkage and spine elimination that persisted for up to 24 h ([@B334]), but in general these synaptic dynamics are confined to critical periods of synaptogenesis during defined developmental windows.

ACTIVITY-DEPENDENT TRANSCRIPTIONAL AND TRANSLATIONAL REGULATION OF SYNAPTOGENESIS
---------------------------------------------------------------------------------

Activity-dependent gene transcription clearly leads to developmental changes in synaptic connectivity. Mouse studies of the transcriptional regulator methyl CpG binding protein 2 (MeCP2) are one elegant example, with knock-in mouse lacking the *neuronal activity-induced phosphorylation* (NAIP) sequence showing increased excitatory synaptogenesis ([@B247]). MeCP2 is phosphorylated in response to activity and subsequent Ca^2+^ influx (CaMKII-dependent), leading to regulation of dendritic branching, spine morphogenesis, and A-D induction of brain-derived neurotrophic factor (BDNF) transcription ([@B437]). Importantly, MeCP2-deficient mice exhibit delayed maturation of cortical synaptogenesis and neuronal architecture defects ([@B139]), and human MeCP2 mutations are causally associated with the ASD Rett syndrome ([@B6]). Indeed, many ASD candidate genes are expressed synaptically to modulate synapse function/morphology, and are directly regulated by synaptic activity ([@B441]). Calcium influx has a profound impact on gene transcription ([@B163]). As one example, A-D Ca^2+^ influx leads to dephosphorylation of myocyte enhancing factor 2 (MEF2) by calcineurin, causing dissociation with histone deacetylases, CBP recruitment and ultimately, transcription-dependent synapse elimination ([@B133]; [@B17]; [@B330]). MEF2 activation also leads to suppression of excitatory synapse number via Arc ([@B133]; [@B134]), perhaps through Arc-mediated AMPA receptor internalization ([@B298]). This MEF2-regulated synapse elimination has been correlated with the acquisition of learning and memory abilities ([@B17]), such as those impacted in ASD disease states. Activity similarly regulates cAMP response element-binding protein (CREB), serum response factor (SRF), FBJ murine osteosarcoma viral oncogene (Fos; [@B161]), and neuronal PAS domain protein 4 (NPAS4; [@B251]), leading to the A-D transcriptional regulation of synaptic proteins, including ASD-associated BDNF, Arc, and ubiquitin-protein ligase E3A (Ube3A; [@B79]; [@B163]). CREB and NPAS4 transcriptional activity, via BDNF A-D activation, also leads to a reduced number of inhibitory synapses on excitatory neurons ([@B185]; [@B251]), suggesting roles in the developmental regulation of E/I ratio.

Activity-dependent localized synaptic translation permits a rapid and synapse-specific response, which is particularly important in governing the multitude of differentially active synapses occurring at a distance from the cell body. RNA-binding proteins and translational regulation have been demonstrated in both axonal growth cones and mature axons ([@B187]), ostensibly permitting local protein production in presynaptic boutons. Highly motile RNA granules containing inactive ribosomes ([@B234]; [@B117]), suggest neurons have evolved mechanisms to bypass translation initiation locally at the synapse ([@B85]; [@B22]). Assays of local translation using ribopuromycylation to visualize ribosomes associated with nascent peptide chains ([@B95]) demonstrate that mRNAs are transported alongside paused polyribosomes at hippocampal synapse, thereby bypassing the rate-limiting step of translation initiation ([@B158]). Importantly, these polyribosomes co-localize with RNA-binding FMRP and Staufen 2 ([@B8]; [@B117]; [@B292]; [@B94]; [@B238]), and defects in A-D translational control can lead to ASD states, with unregulated translation causing synaptic impairment driving behavioral dysfunction ([@B351]). This topic will be explored at length in Part 2.

The strongest link between translation control and A-D synaptogenesis is the RNA-binding FMRP, which regulates translational initiation ([@B292]), mRNA transport ([@B21]), and translational elongation of mRNAs encoding synaptic proteins ([@B94]). FMRP is strongly upregulated during critical periods of neural circuit refinement, where it associates with mobile RNA granules in dendrites, spines, filopodia, and growth cones that translocate in response to the level of neuronal activity ([@B8]; [@B81]). Importantly, FMRP is positivity upregulated by neuronal activity ([@B7]; [@B140]; [@B378]; [@B405]), and regulates multiple A-D processes including synapse elimination ([@B324]). Studies at the *Drosophila* NMJ first demonstrated that FMRP negatively regulates cytoskeletal targets, including the MAP1B/Futsch ([@B435]) mediator of microtubule-associated synaptic growth ([@B345]). Interestingly, A-D transcriptional and translational control are linked through FMRP, as the activity of MEF2 in synapse elimination is wholly dependent on FMRP function, and occurs cell autonomously in the postsynaptic neuron ([@B324]). In *Fmr1* knockout (KO) hippocampal culture, acute expression of FMRP (via timed transfection) at an early postnatal period leads to synapse growth, but FMRP during the second postnatal week led to suppression of synapse formation ([@B431]). Interestingly, MEF2 activity is progressively increased upon depolarization (via high K^+^ treatment) over the same developmental period ([@B431]). These recent studies highlight both the impact of FMRP on synaptic growth and the importance of developmental timing within critical periods of development. In the following section (Part 2) we will elaborate the molecular details of FXS and other ASDs, highlighting A-D changes in the development of synaptic connectivity.

PART 2: ACTIVITY-DEPENDENT MECHANISMS IN ASD DISEASE STATES
===========================================================

For ASD diagnosis, children must display three core symptoms before 3 years of age: (1) atypical social behavior, (2) disrupted verbal/non-verbal communication, and (3) unusual patterns of restricted interests or repetitive behaviors ([@B150]). It has been proposed that a "disconnect" between brain regions involved in higher-order associations lies at the root of these ASD behaviors ([@B137]; [@B86]; for historical context, [@B151],[@B152]). For example, this disconnect may occur between a pair of higher-order association cortices (or several such centers), which represent input from multiple sensory modalities in cortical space ([@B150]). More evidence for this disconnect theory comes from prefrontal cortex and anterior cingulate disconnection for joint attention (foundation of language and social behavior; [@B286]), and demonstrated disconnect in functional magnetic resources imaging (fMRI) studies ([@B228]). The root of this hypothesis is based on the hierarchical development of cortical circuitry ([@B239]; i.e., disrupted development of the initial architecture, e.g., via shifts in critical periods) results in faulty substrates for subsequent A-D mechanisms that are crucial for reorganization, pruning, and solidification of synapses within circuits. Primary sensory cortices develop progressively, with critical periods that are variable in time and often non-overlapping ([@B235]). Furthermore, individual modalities develop progressively, as the critical periods of rodent somatosensory cortex begin at the subcortical level and then progress to cortical levels ([@B129]). The "missed window" theory of ASDs may help explain the root of auditory, visual, and somatosensory dysfunction in information processing, which drives the socialization and communication deficits defining ASDs ([@B239]). In terms of basic brain architecture, ASDs may emerge through faulty subcortical development, which precedes thalamic as well as subsequent cortical development ([@B235]). Evidence for this theory includes early incidence of motor developmental delay, social impairment, and epileptic seizures ([@B441]).

The hierarchical model of ASD brain development is built upon evidence that alterations in primary sensory modalities underlie higher order cognition defects. Broadly speaking, these primary sensory alterations appear to lessen in severity with age, although the severity of primary sensory impairments clearly correlates with the degree of social interaction impairment ([@B28]; [@B365]). Neuronal activity is essential for circuit development ([@B243]; [@B368]), and this activity is both intrinsically generated ([@B156]; [@B343]) and sensory derived, as shown in primary visual cortex ([@B360]). However, this A-D component of circuit development is obviously built upon genetic foundations, and several hundred genes are associated with ASDs ([@B369]). Clinical characterizations of ASDs are highly suggestive of A-D synaptic defects ([@B386]; [@B114]). For example, FXS patients display hypersensitivity to numerous sensory stimuli ([@B279]), as well as abnormal sensory gating in prepulse inhibition trials ([@B180]). In addition, attention deficit/hyperactivity disorder ([@B288]) and developmentally transient epilepsy are also associated with FXS ([@B289]; [@B33]) strongly indicating a core A-D impairment.

Although it is understandably difficult to model ASD behaviors in animals, several recent studies demonstrate inventive ways to address this essential issue. For example, *Fmr1* KO mice display many behavioral disruptions similar to human FXS patients, including susceptibility to audiogenic seizure, hyperactivity, learning and memory deficits, and social interaction abnormalities ([@B225]; [@B25]; [@B168]). Some studies report that *Fmr1* KO mice show increased anxiety-related activity during social interaction ([@B280]), whereas other studies show *decreased* anxiety in open field studies ([@B276]). It is quite clear that behavioral phenotypic effects are heavily dependent on genetic background ([@B367]). However, *Fmr1* KO mice in the C57 background show consistent impairments in social interaction behaviors ([@B16]). Research in mice has also focused on single sensory modalities, showing that *Fmr1* KO mice display altered auditory processing ([@B346]). Although higher cognition is difficult to test in mice, recent research using a touch-screen operant conditioning paradigm (which facilitates a conflict between sensory-driven and task-dependent signals, thereby increasing cognitive load) demonstrates that *Fmr1* KO mice display defects in learning under heavy cognitive demand ([@B103]). The *Drosophila* FXS model similarly shows disruptions closely resembling human FXS patients, including hyperactivity, learning/memory deficits, and social interaction abnormalities ([@B47], [@B48],[@B49]; [@B76], [@B77]; [@B381]).

CRITICAL PERIOD DEVELOPMENT OF E/I RATIOS IN ASDs
-------------------------------------------------

Autism spectrum disorders have been ascribed to altered E/I synaptic balance, which likely reflects defects in A-D synapse elimination/addition specific to different classes of synapse ([@B347]; [@B179]; [@B335]; [@B148]). Neural circuits must carefully balance excitatory and inhibitory connections during critical period development, and theories of synaptic homeostasis posit that compensatory alterations prevent runaway signaling ([@B391]; [@B259]). The appearance of altered E/I ratio is linked with critical periods of brain development, as runaway hyperexcitable circuits fail to mature properly without inhibitory input ([@B347]; [@B341]). In support of this idea, postmortem neocortex tissue from ASD patients shows reduced vertical arrays of glutamatergic and GABAergic mini-columns and disordered peripheral neuropil space ([@B58]). Moreover, ASD postmortem studies reveal a reduction in glutamic acid decarboxylase (GAD), the rate-limiting enzyme in GABA synthesis ([@B125]). On the postsynaptic membrane, samples from ASD patient brains also contain reduced GABA-A receptor expression ([@B123],[@B124]). Crucially, excitatory circuits must be balanced by GABAergic inhibitory interneurons that form connections progressively during late-stage critical period development ([@B12]). Competing theories of both hypoinhibition (GABAergic deficits) and hyperexcitation (excitatory excess) underlying autistic disease states are well known ([@B148]). However, many results support hypoinhibition models that complement hyperexcitation models; these models are not necessarily mutually exclusive and may represent two counterbalancing underpinnings of ASD disease states.

Fragile X syndrome is among the best-characterized ASD disease states. FMRP is found at the synapse, positivity upregulated by neuronal activity and regulates A-D processes including synapse elimination (**Figure [2](#F2){ref-type="fig"}**; [@B7]; [@B140]; [@B378]; [@B404]; [@B324]). FXS may be characterized by a failure to remove immature synaptic connections and properly balance E/I synapse ratio during critical period development ([@B80]; [@B197], [@B198]; [@B141]; [@B273]). For example, *Fmr1* KO mice display brain-region specific increases and decreases in GAD expression ([@B102]; [@B2]); increased in cortex, brainstem, and diencephalon ([@B116]), and decreased in amygdala ([@B301]). FMRP also regulates GABA-A receptor expression ([@B254]), as *Fmr1* KOs show reduced GABA-R subunit mRNA ([@B102]; [@B144]) and protein ([@B116]; [@B89]; [@B2]). Recent work suggests that the timing rather than the absolute expression levels of GABA~A~Rs α1, α2, and gephyrin are altered in *Fmr1* KO mice ([@B231]), once again supporting the theory of critical period dysfunction. It is now clear that GABAergic changes are regionally specific, as *Fmr1* KO mice display reduced inhibitory synapses within the basolateral amygdala ([@B301]), yet increased inhibitory synapses are noted in CA1 region of hippocampus ([@B90]), providing direct evidence of E/I imbalance. *Fmr1*-deficient mice exhibit defects in GABAergic neocortical circuits ([@B356]), with differences in the neocortical E/I balance ([@B153]). There is some conflicting data from functional GABAergic studies, with decreased tonic inhibition in recordings from subicular neurons ([@B89]), decreased tonic and phasic inhibition in the amygdala ([@B301]), and increased inhibitory transmission in striatal spiny neurons ([@B60]) all reported in the mouse FXS model. A recent study reports a cell-specific presynaptic role for FMRP in excitatory neurotransmission onto inhibitory interneurons in layer 4 of mouse cortex ([@B315]), with mice mosaic for *Fmr1* displaying decreased glutamate release probability. This defect was not observed in neurotransmission between excitatory neurons, showing a cell-specific role for FMRP and a potential mechanistic basis for E/I imbalance in the FXS disease state.

![**Synaptic changes in the Fragile X syndrome disease state.** Schematic depictions of glutamatergic synapses in wild type **(A)** and FXS **(B)** conditions showing molecular changes in the response to activity. Data reflect human FXS patient studies, as well as mouse and *Drosophila* FXS animal models. **(A)** In wild-type, FMRP regulates glutamate release and anterograde *trans*-synaptic signaling (e.g., Jeb and Wnt), but does not demonstrably affect retrograde signaling (e.g., BMP; [@B136]). FMRP acts as a translational repressor limiting synthesis of cytoskeletal regulators (e.g., MAP1B, Rac1, PAK; [@B435]; [@B50]; [@B106]), AMPA-R regulators (e.g., Arc; [@B84]; [@B298]), MMPs ([@B37]), and heparan sulfate proteoglycans (HSPGs: Dlp and Syd; [@B92]). FMRP is activity regulated downstream of mGluR signaling, but likely responds to other activity signals as well. **(B)** In the FXS state, lack of FMRP leads to increased neurotransmission, increased HSPG production (which in turn sequester anterograde *trans*-synaptic signaling molecules), increased MMP synthesis/activity, cytoskeletal remodeling defects, and changes in postsynaptic AMPA glutamate receptor cycling. Two engineered rhodopsin variants allow non-invasive modulation of neural activity: channelrhodopsin responds to 480 nm blue light to gate Na^+^ influx (depolarization), and halorhodopsin responds to 550 nm amber light to gate Cl^-^ influx (hyperpolarization; [@B130]).](fncel-08-00030-g002){#F2}

The opposing side of the E/I ratio -- excitatory signaling -- is even better explored in ASD models, especially in the FXS disease state ([@B347]). Excitatory neurons are intrinsically more excitable in *Fmr1* KO mice ([@B153]), with elevated Ca^2+^ signaling ([@B157]) and excitatory networks that are structurally hyperconnected (although individual excitatory connections are slower; [@B382]). Excessive mGluR signaling, as a reporter of glutamatergic synapse activity state, is widely reported ([@B25]; [@B23]). The mGluR theory of FXS suggests that disease symptoms are due to exaggerated downstream consequences of aberrant mGluR1/5 signaling. Crucially, FMRP is locally synthesized in response to mGluR activation ([@B410]), and mGluR-mediated hippocampal LTD is exaggerated in *Fmr1* KO mice ([@B192]; [@B300]). FMRP is dephosphorylated (by PP2A) upon stimulation of group I mGluRs, which leads to a rapid increase in translation ([@B293]). In line with these studies, mGluR5 heterozygosity rescues many of *Fmr1* KO mice phenotypes ([@B109]). Also, group 1 mGluR antagonists \[e.g., MPEP (2-methyl-6-(phenylethynyl)-pyridine)\] ameliorate several behavioral phenotypes in *Fmr1* KO mice ([@B424]; [@B69]). Recent mechanistic studies show that mGluRA activation starts a cascade of events leading to FMRP phosphorylation and subsequent synthesis of Arc, and ultimately mGluR-associated LTD ([@B298]). In addition, activation of serotonin 7 receptors (5-HT7) can reverse mGluR-induced AMPA internalization in FXS model mice, effectively correcting mGluR-LTD ([@B84]). Although initial formation of auditory cortex is normal in *Fmr1* KO mice, mutants fail to undergo experience-dependent reorganization, suggesting an altered auditory critical period that is mGluR-dependent, as MPEP suppressed the sound-induced reorganization phenotype ([@B217]). Sensory-dependent reorganization of auditory cortex has been explored at length, with A-D changes in hippocampus including neurogenesis, learning and memory, and neural connectivity ([@B64]).

There are some caveats with the mouse FXS model. One issue is the timing of the FMRP loss, as in mouse models the *Fmr1* gene is deleted and therefore not expressed ([@B277]), whereas the human gene is silenced via methylation during embryonic development, but is expressed at early stages ([@B418]). Furthermore, human patients may display *Fmr1* mosaicism across cell types, due to methylation specificity or variable presence of a premutation ([@B371]). Finally, mouse *Fmr1* phenotypic effects are often surprisingly mild, transient, and heavily dependent on genetic background ([@B367]). Although the *Drosophila* FXS model does not address the first two issues, *dfmr1* null phenotypes are generally both more robust and more penetrant ([@B381]). Excitatory synaptic signaling (glutamatergic and cholinergic) pathways have both been extensively studied in the *Drosophila* FXS model (**Figure [2](#F2){ref-type="fig"}**). Electrophysiological studies indicate increased excitability, A-D synaptic vesicle cycling and neurotransmission in *dfmr1* null glutamatergic synapses ([@B435]; [@B146]). *Drosophila* FMRP and sole mGluR (DmGluRA) display mutual feedback regulation, as FMRP expression increases with the loss of *dmGluRA*, and DmGluRA expression increases with loss of *dfmr1* ([@B311]). Crucially, many FXS phenotypes are ameliorated by feeding of mGluR antagonists (e.g., MPEP; [@B271]; [@B70]), and MPEP phenocopies the genetic loss of *dmGluRA* ([@B310]; [@B311]). Importantly, *dfmr1*; *dmGluRA* double null mutants partially rescue excitatory defects witnessed under high frequency stimulation paradigms ([@B339]), providing a partial genetic basis for a hyperexcitable state in FXS. In the absence of FMRP, increased mGluR function leads to decreased cyclic AMP, which is further correlated with deficits in olfactory learning and memory ([@B210]). Intriguingly, cAMP positively regulates transcription of *dfmr1*, via PKA and CREB ([@B210]), thereby linking glutamatergic signaling and FMRP at the nucleus. In addition, recent work in our laboratory has identified alterations in the inhibitory circuitry of *dfmr1* null flies. *dfmr1* mutants are characterized by reduced GAD expression in the adult brain, developmental stage-specific dysmorphia in GABAergic axons innervating the MB calyx, and altered GABAergic Ca^2+^ dynamics ([@B149]). This data importantly implicates altered inhibitory neurotransmission in the *Drosophila* model of FXS, and further validates the conservation of FMRP function in the fruit fly brain.

DYSMORPHIC SYNAPSES IN ASD DISEASE STATES
-----------------------------------------

Most ASD human studies on synaptic dysmorphia focus on the dendritic domain. For example, ASD patients display increased dendritic spine densities on cortical projection neurons ([@B194]). FXS patients also display elevated spine density, with processes displaying elongated, "tortuous" structures ([@B198]), perhaps suggestive of defects in synapse elimination. Similar dendritic dysmorphia are common in many other neurological disease states ([@B267]; [@B333]; [@B212]), which may reflect developmental arrest or an attempted compensation for the lack of functionally mature spines ([@B132]). In particular, it should be noted that these dendritic phenotypes are not restricted to the autism spectrum (sociolinguist deficits), as individuals with schizophrenia (perception deficits) and Alzheimer's disease (memory dysfunction) also display abnormal dendritic spine architectures ([@B320]). These three forms of neurological dysfunction are distinct in symptomology, yet this specificity may be rooted in the timing and onset of synaptic dysfunction (**Figure [1B](#F1){ref-type="fig"}**).

Protrusion dynamics are just as important for synaptogenesis in genetic model systems ([@B440]; [@B257]). In the mouse FXS model, for example, there is delayed functional spine formation in the hippocampus ([@B53]), and ultimately fewer spines with mature, bulbous morphology ([@B197]). SD leads to changes in spine protrusion dynamics in neonatal mice ([@B243]), demonstrating A-D regulation. Specifically, *Fmr1* KO mice deficits may result from deficits in experience-dependent plasticity during critical periods of synaptic refinement ([@B109]; [@B56]). During *in vivo* time lapse imaging through cranial windows in neonatal mice, layer 2/3 neurons show a dramatic decrease in dendritic spine dynamics during the first 2 weeks as mushroom-shaped spines replace filopodia and protospines, whereas *Fmr1* KO mice show developmental delays in the downregulation of spine turnover and the transition to mature spines ([@B88]). Importantly, mGluR blockage accentuated these phenotypes in *Fmr1* KO mice ([@B88]), providing a different link to A-D synaptic remodeling in the FXS disease state.

The dynamic nature of dendrites enhances their ability to sample the extracellular space for suitable presynaptic terminals ([@B440]; [@B51]). Immature synapses from as adhesions between dendritic filopodia and axons ([@B132]). Perturbations in these dynamics lead to altered synaptogenesis, for example, as demonstrated in Ephrin B-deficient ([@B213]) and neurotrophin-deficient ([@B257]) conditions. Following initial contact, spine dynamics are necessary for A-D remodeling ([@B243]; [@B427], [@B428]; [@B183]), and then strongly downregulated at the end of the critical period of synapse selection ([@B440]). In FXS animal models, the failure to stabilize dendritic spines in developmental critical periods suggests *Fmr1* null protrusions have problems maintaining proper balance between stability and dynamism ([@B9]; [@B323]), resulting in fewer mature synaptic connections ([@B88]). FMRP presumably modulates synaptic stability through regulation of mRNAs coding for dendritic spine regulators ([@B13]; [@B21]), such as the key postsynaptic scaffold PSD-95 (postsynaptic density protein 95) as one example (**Figure [2](#F2){ref-type="fig"}**; [@B429]). Recent reviews outline the spine dysmorphia in the mouse FXS model in more detail ([@B174]).

Differences in axonal development in the mouse FXS model have not been as extensively studied. However, FMRP is localized at axon growth cones, which are far less dynamic in*Fmr1* KO mice ([@B9]). More thorough studies in the *Drosophila* FXS model demonstrate progressive differences in axonal projection and synaptic process pruning in the central brain MB of *dfmr1* null mutants ([@B381]). The *Drosophila* model demonstrates defects in the development of neuronal architecture ([@B435]) and inappropriate A-D pruning ([@B379]) throughout the brain. For example, the synapses of small ventrolateral neurons (sLNvS) in the circadian regulation circuitry are overelaborated in *dfmr1* nulls ([@B105]; [@B147]), a developmental phenotype that can be rescued only during the late pupal/early adult critical period, but not in early pupal stages or in mature adult stages ([@B147]), demonstrating a transient critical period requirement for FMRP. In the MB circuit, FMRP is required to limit outgrowth during an early phase and to subsequently prune synaptic branches in a later phase, and both phases are dependent on activity input ([@B378]). Furthermore, MB neurons in *dfmr1* nulls demonstrate age-dependent increases in calcium signaling dynamics, as well as deficient expression of several calcium-binding proteins ([@B380]), suggesting activity is driving a calcium signaling cascade coupling structural and functional developmental changes in the FXS disease state. Collectively, these defects all map to the early-use, A-D critical period of synaptic remodeling.

A-D TRANSLATION MISREGULATION IN THE ASD FRAGILE X SYNDROME
-----------------------------------------------------------

Autism spectrum disorders have been linked to hundreds of genes ([@B1]; [@B386]; [@B100]), and the number keeps jumping higher, with candidates in pathways affecting many distinct neuronal functions ([@B98]). Importantly, however, many of these genes are modulated by neural activity, either directly or indirectly ([@B283]; [@B61]; [@B114]), and a number are known to be involved in A-D neural circuit modification ([@B386]). Rare *de novo* mutations have implicated a large network of genes directly involved in synaptogenesis and synaptic function ([@B154]). Nevertheless, ASD modeling is made difficult by the underlying genetic diversity, and this difficulty is compounded by the array of symptoms described in human conditions and debates about appropriate genetic models ([@B87]). The genetic bases of autism can be divided into a number of molecular groups: (1) chromatin remodeling, (2) cytoskeletal dynamics, (3) synaptic scaffolds, (4) neurotransmitter receptors and transporters, (5) second messengers, (6) cell adhesion molecules, and (7) secreted proteins ([@B322]). Clearly the genetic basis of ASDs is massive area, and we focus here only on the FXS disease state, which may be an A-D translation control point for a number of these protein classes.

The monogenic FXS disease state ([@B397]) is typically caused by an unstable 5′ trinucleotide expansion in the promoter region of the *Fmr1* gene leading to hypermethylation and transcriptional silencing ([@B241]). FXS patients exhibit delayed developmental trajectories, working memory deficits, circadian defects, hypersensitivity to sensory input, seizures, increased anxiety and hyperactivity ([@B171]), and a 30% comorbidity with autism ([@B438]). Furthermore, FMRP may be associated with other neurological disease states, as schizophrenic patients have reduced FMRP in the periphery ([@B230]) and cerebellum ([@B126]), correlating with poor performance on perceptual integration tasks ([@B214]). The expanding web of FMRP associations ([@B52]; [@B167]; [@B122]) underlines the importance of this mRNA-binding translational regulator, with hundreds of candidate mRNA targets ([@B281]; [@B94]; [@B14]). FMRP forms large cytosolic ribonuclear particles (RNPs), which are associated with mRNA transport, stability, and translation control ([@B14]). RNP transport dynamics are altered in *Fmr1* KO mice, with reduced kinesin-associated mRNAs ([@B104]). However, FMRP does not appear to be necessary for steady-state maintenance or constitutive localization of the majority of its target mRNAs ([@B370]; [@B104]), although direct measurement of protein synthesis in hippocampal slices ([@B109]), hippocampal culture ([@B302]), and synaptosomes ([@B285]) shows global elevations in the *Fmr1* KO mouse.

Fragile X mental retardation protein is such an important focus because it is poised to directly and quickly respond to activity changes at the synapse. FMRP transports mRNA within the neuron and specifically at synapses in an A-D manner via association with microtubule-associated motor proteins ([@B209]; [@B8]; [@B131]; [@B104]; [@B63]). Targets of FMRP ([@B36]) include the small GTPase *Rac1* and its effector p-21 activated kinase (*PAK*), functioning as actin regulators ([@B46]). Rac1 is necessary for dendritic spine development, loss of FMRP leads to over-activation of Rac1 (**Figure [2B](#F2){ref-type="fig"}**), and Rac1 pharmacological inhibition leads to suppression of LTD in *Fmr1* KO mice ([@B50]). In addition, A-D stimulation of hippocampal synapses leads to increased phosphorylated PAK in wild-type, but not *Fmr1* KO mice, and mutants were unable to maintain actin cytoskeletal A-D changes ([@B65]). Moreover, small molecule inhibition of PAK suppresses *Fmr1* null phenotypes including dendritic spine morphology, seizures, hyperactivity, and repetitive movements ([@B106]). Another target, PSD-95 is an adaptor protein associated with glutamatergic receptors ([@B358]); mice deficient in PSD-95 show dendritic spine dysmorphia in striatum and hippocampus ([@B398]). FMRP may regulate PSD-95 partially through stabilization of PSD-95 mRNA, a process that is enhanced with mGluR activation (**Figure [2A](#F2){ref-type="fig"}**; [@B429]). FMRP also associates with *futsch/MAP1B* mRNA, a microtubule regulator of synaptic growth ([@B345]), that can be localized at the growth cone of developing axons ([@B9]), and is localized within FMRP--RNP granules in cultured hippocampal neurons ([@B8]). FMRP and *futsch* associate in co-immunoprecipitation assays, and its expression is inversely correlated with FMRP expression ([@B435]). Importantly, *futsch* loss of function corrects the synaptic overgrowth phenotype in *dfmr1* nulls (**Figure [2B](#F2){ref-type="fig"}**; [@B435]). Application of the axon guidance molecule Semaphorin-3A (Sema3A) to hippocampal culture leads to MAP1B protein synthesis, but this response is attenuated in *Fmr1* null neurons ([@B246]), thereby linking the activity of an axon guidance molecule with local FMRP-dependent translation. More recent work has shown that FMRP regulation of *futsch* is downstream of BMP and Spartin signaling ([@B291]), thereby linking a key *trans*-synaptic signaling pathway with cytoskeletal changes in presynaptic neurons.

Several recent studies have provided new mechanistic insights about FMRP function at the synapse. Two recently identified FMRP targets are striatal-enriched protein tyrosine phosphatase (STEP) and amyloid precursor protein (APP), which appear to underlie at least a portion of mouse *Fmr1* phenotypes, as genetic reduction of either can suppress audiogenic seizure, anxiety, and social deficits in the disease model condition ([@B412]; [@B155]; **Figure [2](#F2){ref-type="fig"}**). Another target of FMRP is *Arc* mRNA ([@B430]), an A-D immediate early gene ([@B252]) strongly linked to synaptic function ([@B313]). Importantly, Arc protein functions to stimulate endocytosis of AMPA glutamate receptors ([@B74]), an action correlated with the A-D induction of LTD ([@B313]). FMRP plays an important modulatory role in this A-D process, acting as a translational repressor of *Arc* synthesis during mGluR-LTD ([@B298]). FMRP also regulates several potassium ion channels. For example, FMRP interacts with Kv3.1b mRNA in brainstem synaptosomes, and the A-D increase in Kv3.1b channel expression in wild type mice is abolished in *Fmr1* null mice ([@B372]). Moreover, FMRP can directly interact with potassium channel proteins to regulate channel kinetics, including Slack channels ([@B55]) and the β4 subunit of BK channels ([@B99]). Therefore, FMRP can no longer be described as solely a translational regulator, with protein--protein interactions regulating excitability demonstrating an additional vital role for FMRP function.

The final area of focus for FMRP regulation lies in the extracellular space. Both mouse and *Drosophila* FXS models have recently been documented to show large increase in the levels of synaptic matrix metalloproteases (MMPs), a family of extracellular proteases involved in synaptic development, function, and plasticity (**Figures [2A,B](#F2){ref-type="fig"}**; [@B342]). MMPs cleave secreted as well as membrane-anchored proteins during synaptogenesis and A-D synaptic remodeling ([@B121]). Specifically, MMP-9 expression and activity are increased in *Fmr1* KO mice ([@B37]), with MMP-9 locally translated at synaptodendritic domains in an A-D manner ([@B111]). MMP-9 mRNA is transported and regulated by FMRP, and increased MMP-9 expression is found in *Fmr1* null synaptosomes from mouse hippocampus ([@B200]). Crucially, a drug inhibitor of MMPs, minocycline, effectively restores synaptic architecture and behavioral defects in the mouse FXS model (**Figure [2](#F2){ref-type="fig"}**; [@B37]). The mechanistic link between MMPs and ASDs may lie with MMP substrates, especially the HSPGs, which are well-established proteolytic targets of MMPs ([@B71]). HSPGs bind a variety of molecules, including growth factors, morphogens, and cell surface receptors, effectively modulating a hosts of biological functions ([@B42]). In BTBR autism mouse models ([@B352]), hippocampal sclerosis (HS) immunoreactivity is reduced ([@B275]). Conditional inactivation (neuronal specific) of *Ext1*, an essential enzyme for HS synthesis, leads to defective glutamatergic neurotransmission and behavioral abnormalities similar to autistic phenotypes ([@B196]). Disruption of HSPGs in *Drosophila* leads to *trans*-synaptic signaling defects at the NMJ ([@B92]), causing impairments of synaptic structural and functional development. Moreover, in the *Drosophila* FXS model, both MMP mutation and the minocycline MMP inhibitor (MMPIs) treatment effectively suppresses synaptic architecture defects in motor neurons, clock neurons, and neurons of the central brain MB learning/memory center ([@B364]). Perhaps linking these two mechanisms, the *Drosophila* FXS model displays dramatic upregulation of synaptic HSPGs (**Figure [2](#F2){ref-type="fig"}**), including a GPI-anchored Glypican and transmembrane Syndecan (Sdc; [@B136]). These elevated co-receptors in turn inappropriately sequester Jelly Belly (Jeb) and Wnt Wg *trans*-synaptic signaling ligands to alter intercellular communication between pre- and postsynaptic cells during synaptogenesis (**Figures [2A,B](#F2){ref-type="fig"}**). Genetic correction of the synaptic HSPG upregulation in *dfmr1* null mutants corrects both structural overelaboration and elevated neurotransmission ([@B136]), demonstrating this signaling mechanism to be causative to A-D synaptogenic defects in this FXS disease state model. Based on these extensive studies in mice and flies, MMPIs are currently in development for FXS therapeutics as discussed below.

ASD THERAPEUTIC AVENUES
-----------------------

The A-D model of ASDs, especially as it applies to the regulation of critical period development of appropriate E/I synaptic ratios, suggests a number of therapeutic strategies. For example, the overabundant mGluR signaling theory underlying FXS dysfunction is supported by numerous mGluR mutant studies in mouse and *Drosophila* animal models ([@B25], [@B24]; [@B23]; [@B271]; [@B109], [@B108]; [@B310]; [@B107]; [@B311]; [@B339]). Importantly, mGluR antagonists (such as MPEP) effectively rescue many of the mouse and *Drosophila* FXS model cellular and behavioral defects associated with FXS ([@B271]; [@B310]; [@B47]; [@B107]; [@B68]; [@B108]). MPEP is not available for human use due to toxicity, but new generation mGluR antagonists are in development ([@B244]; [@B403]; [@B325]). For example, chronic application of the mGluR antagonist CTEP suppresses learning and memory deficits and leads to regional improvements in brain function in *Fmr1* KO mice, as determined by perfusion imaging as an indirect measure of neural activity ([@B276]), although it is important to note that CTEP also affected wild-type learning and memory. This first use of functional imaging in a mouse ASD model is an important step forward. Current FXS patient clinical trials include other mGluR antagonists (e.g., mavoglurant; [@B143]) as well as GABA-B receptor agonists (e.g., arbaclofen; [@B176]). Fenobam, a selective mGluR antagonist, improved prepulse inhibition in 6 of 12 FXS patients ([@B34]). mGluR reverse agonists in phase II and III clinical trials were recently extended to younger children ([@B244]), recognizing the early developmental focus likely necessary for effective intervention. For illustration, the rescue of spine morphology in cultured neurons from *Fmr1* KO mice by mGluR blockage is effective in young neurons but less so in older neurons ([@B373]). Thus, it is important for interventions to target A-D critical periods.

On this opposing side of the E/I balance lies the therapeutic potential to increase GABA levels or potentiate GABA receptors, with the goal to alleviating FXS symptoms of hypoinhibition ([@B308]; [@B78]). Altered GABAergic inhibition is a common thread in many neurodevelopmental disorders and represent an important focus for therapeutics. Pharmacological approaches to GABAergic modulation address several components of inhibitory neurotransmission, including the GABA reuptake blockers Riluzole ([@B264]; [@B199]; [@B119]) and Tiagabine ([@B297]), GABA~A~R activators Ganaxolone ([@B35]; [@B336]) and Gaboxadol ([@B97]; [@B258]; [@B301]), GABA~B~R activator Arbaclofen ([@B304]), and Vigabatrin, an inhibitor of GABA catabolism ([@B135]; [@B82]). Acamprosate is also interesting, as a drug that both antagonizes mGluR5 ([@B44]) and agonizes GABA~A~Rs ([@B262]). A small uncontrolled trial with three adult FXS patients showed improvement in social behavior and communication after 16--28 weeks on acamprosate ([@B120]), and similar gains in social communication were found in a small uncontrolled sample of autistic children ([@B118]).

Alternative pharmaceutical approaches to FXS focus on MMP and perhaps HSPG function in the synaptomatrix ([@B364]; [@B91]; [@B92]; [@B136]). One obvious approach is the use of MMPIs, of which a large collection has been developed for human clinical trials on inflammatory and vascular diseases ([@B188]). For example, the tetracycline-derivative minocycline acting as an MMPI spurs maturation of hippocampal dendritic spines and represses anxiety and memory defects in the FXS mouse model ([@B37]), and similarly suppresses synaptic architecture defects in motor neurons, clock neurons, and MB learning/memory center neurons in the *Drosophila* FXS model ([@B364]). The drug therefore offers a directed approach toward deficits in A-D mechanisms at the synapse as it aims to correct overactive MMP in the absence of FMRP. Minocycline has previously been successful in treating a variety of neurological disorders, including multiple sclerosis, Huntington's disease, Parkinson's disease, and Alzheimer's disease ([@B406]; [@B72]; [@B219]). Minocycline treatments led to a long-term reduction in hyperactivity and audiogenic seizures in young, but not old mice ([@B93]). In human trials, minocycline led to improved language, behavior, and attention in FXS patients in an uncontrolled study ([@B394]), and a recent 3-month double-blind, placebo-controlled trial with young FXS patients showed improvements in anxiety, mood, and clinical global impression (CGI) of FXS individuals given minocycline ([@B242]). The mechanistic link between minocycline and MMPs in human patients has also been explored, as reduced MMP-9 activity correlates with CGI improvements in FXS patients ([@B112]). Finally, the PAK-associated cytoskeletal changes in FXS models have been pharmaceutically targeted, with significant suppression of FXS phenotypes in the *Fmr1* null mouse ([@B106]). There may be a clinical path forward targeting PAK and/or downstream cytoskeletal perturbations.

A quite different avenue for ASD treatment targets A-D critical period development via environmental enrichment and training intervention following early diagnosis ([@B96]; [@B422]). To illustrate the impact of environmental input on cognitive development, Romanian orphans who received limited sensory stimulation can have profound social and cognitive defects, and many develop post-institutional autistic syndrome ([@B181]), suggesting that an ASD-like state can be achieved through purely environmental impoverishment. Thankfully many of these children make significant cognitive and social gains upon adoption and placement into enriched environments ([@B295]). Importantly, enriched environments increase sensory input activity and have profound effects on A-D synaptic dynamics ([@B162]; [@B26]; [@B284]). In animal models, FXS mutant mice display a host of striking improvements when reared in enriched environments, including greater spine hippocampal spine density ([@B237]) and improved spike timing long-term potentiation (LTP; [@B274]). As a group of syndromes with strong links to A-D synaptic developmental defects, enrichment approaches are popular in ASD treatments ([@B337]; [@B408]). For example, a peer-mediated theater-based intervention strategy for ASD children showed significant gains in core social deficits ([@B83]). Similarly, a recent 6-month controlled trial showed significant gains in autistic children who underwent sensorimotor enrichment through olfactory and tactile stimulation and exercises for other cross-sensory stimulation ([@B422]). These behavioral intervention strategies are, crucially, focusing on multisensory domains and may enable great improvements in both social and cognitive abilities of ASD children.

PART 3: *IN VIVO* MANIPULATION/READOUT OF ACTIVITY-DEPENDENT CHANGES
====================================================================

The recent emergence of tools to non-invasively drive and monitor neural activity represents a pioneering step forward for A-D neurodevelopmental studies. Compared to the relatively narrow and invasive strategies of traditional electrophysiology ([@B38]; [@B43]), new optogenetic techniques provide simultaneous access to groups of neurons, which can be selectively targeted with a range of transgenic drivers ([@B220]). On the one hand, new optogenetic techniques using engineered rhodopsin variants have enormously advanced our ability to control activity with pulsed application of specific wavelengths of light in defined populations of neurons ([@B130]). On the other hand, optical recording techniques, such as calcium sensors and voltage-sensitive fluorescent reporters, provide individual and massed readouts of neural activity throughout the imaged circuitry, albeit at a cost in sensitivity and temporal resolution compared to electrophysiological recordings ([@B164]; [@B290]). Thus, these new transgenic techniques provide unprecedented abilities to both drive and record *in vivo* neural activity, and therefore show great promise for the systematic dissection of A-D critical period mechanisms at the heart of ASD disease states.

Techniques for detecting neural calcium flux have been progressing for decades ([@B359]; [@B390]), taking advantage of Ca^2+^ dynamics as a readout of neural activity ([@B31]). Resting Ca^2+^ concentrations in neurons are typically \<100 nM and rise 10- to 100-fold following a single action potential ([@B32]), providing the ability to monitor spike number, timing, frequency, and levels of synaptic input ([@B425]). Genetically encoded calcium indicators (GECIs), such as the frGECIs and GCamps ([@B229]), have revolutionized *in vivo* Ca^2+^ imaging. The latest generations of GCamp sensors are especially exciting, as they display ultrasensitive kinetics and stably provide readout of neural activity over extensive periods of time ([@B4]; [@B66]). For instance, GCamp6 effectively records neural activity from large groups of neurons to small synaptic compartments, in animals ranging from *Drosophila* to mice ([@B66]). The recent development of red-shifted GECIs reduces tissue scattering, phototoxicity, and background fluorescence, and allows the simultaneous use of other tools, such as ChR2, which is activated with 480 nm light and would therefore overlap and interfere with traditional green fluorescent protein (GFP)-based calcium sensors ([@B3]). The tandem development of multiphoton imaging and GECIs now provide exquisite access for activity monitoring.

Although Ca^2+^ imaging serves as readout for diverse forms of A-D changes (e.g., depolarization, influx, store release, second messenger cascades), the direct detection of changes in membrane voltage would represent a more specific, direct readout of electrical activity. Small fluorescent hydrophobic dyes have long been able to detect changes in membrane potential, and can also be used to characterize propagation of electrical signals through a given circuit ([@B348]). However, these dyes have low penetrance to deep areas of the brain, and are not genetically targetable. Early generations of genetically encoded voltage indicator proteins (GEVIs) overcame some of these limitations ([@B362]; [@B20]), but failed to reliably demonstrate robust signals in intact animals. In contrast, the recently developed ArcLight system is a voltage sensor probes (VSP)-based fluorescent voltage sensor with greatly increased signal-to-noise ratio ([@B203]). In intact *Drosophila* brains, the ArcLight system effectively reports both action potentials and subthreshold events, demonstrating beautiful sensitivity ([@B57]). The *in vivo* applications for this new tool are exciting. For example, ArcLight has provided the ability to record rhythmic activity in *Drosophila* clock neurons, which have so far been inaccessible to electrophysiology approaches ([@B57]). Thus, GEVIs and GECIs are exciting new tools that grant non-invasive and increasingly penetrant representations of *in vivo* neural activity.

OPTOGENETIC CONTROL OF NEURONAL ACTIVITY
----------------------------------------

Optogenetic techniques have revolutionized the ability to direct and dissect A-D processes during critical period development ([@B419]). Delivery of engineered rhodopsin variants into targeted neurons provides a non-invasive means to control neuronal firing rates via pulses of specific wavelengths of light. ChR2 facilitate depolarization of the membrane by gating influx of Na^+^ ions when illuminated by blue light (see **Figure [2A](#F2){ref-type="fig"}**; [@B130]). Conversely, halorhodopsins (eNpHR) respond to amber light by mediating Cl^-^ ion influx, thereby hyperpolarizing the membrane and inhibiting firing (**Figure [2A](#F2){ref-type="fig"}**; [@B433]; [@B160]). To date, most optogenetic studies have been either electrophysiological or behavioral work in mature animals including, for example, an alternative to deep brain stimulation in Parkinson's disease model mice ([@B159]), reduction of anxiety ([@B393]), serotonergic modulation of behavior ([@B407]), dopaminergic depression alleviation ([@B392]), and memory extinction ([@B396]). However, developmental applications of optogenetic A-D modulation are beginning to appear. For example, ChR2-expressing *Drosophila* MB neurons respond to short blue light illumination (6 h) during critical period development with significant decreases in synaptic process branching, but this A-D synaptic pruning is completely abolished in FXS model animals ([@B378], [@B381]). In mouse, ChR2 optogenetic stimulation causes a lasting increase in postsynaptic spine density and increased concentration of CaMKII, when paired with glutamate uncaging ([@B434]). Furthermore, optogenetics is now capable of producing cortical maps, and can be coupled with Ca^2+^ imaging for readouts of activity alterations ([@B316]). In addition, the coupling of optogenetic stimulation and immediate early active gene *NPAS4* mRNA facilitates identification of transfected neurons in mice ([@B29]). The capacity to manipulate A-D neuronal structure and function *in vivo* in a developmental context is simply remarkable, and recent studies highlight the promise of these rapidly evolving techniques.

In the past year, optogenetics techniques have particularly begun to blossom. For example, delivery of ChR2 to thalamic neurons was recently shown to effectively silence cortical seizures in mice ([@B317]). Conversely, expression of eNpHR in hippocampal neurons also provided protection against seizures ([@B374]). Halorhodopsin channels can also provide *in vivo* inhibition of motor activity ([@B253]). The emergence of red-shifted GECIs and optogenetic channels now facilitates dual transgenic manipulation and functional readout in the same animal ([@B3]). Combinatorial dye labeling can also facilitate the simultaneous detection of structural and functional changes without the use of genetics ([@B361]). The development of optochemical G protein-coupled receptors (GPCRs), including light-agonized mGluRs, have been shown to be fast, bistable means to effectively suppress excitability and inhibit neurotransmitter release both in brain slices and *in vivo* ([@B245]). The InSynC (inhibition of synapses with chromophore-assisted light inactivation) technique has been developed to directly inhibit neurotransmitter release, via a genetically encoded singlet oxygen generator (miniSOG) fused to two synaptic proteins, vesicle-associated membrane protein 2 (VAMP2) and synaptophysin ([@B250]). Multiphoton uncaging of glutamate and GABA analogs has been demonstrated on individual dendritic spines in hippocampal slices ([@B173]). Red-shifted excitatory optogenes (ReaChR) have improved membrane trafficking, higher photocurrents and faster kinetics, scatter less in passing through the tissue, and have been capable of driving action potentials in awake mice with illumination through the intact skull ([@B249]).

Despite the justifiable excitement, it is important to note also important caveats to optogenetic applications, particularly for the use in A-D developmental studies. First, it was recently reported that long-term expression of ChR2 can alter axonal morphology in mice ([@B282]). In addition, high-level, long-term expression of fluorescent probes can lead to structural artifacts and phototoxicity ([@B307]). Second, optogenetics are generally delivered through viral means in mammalian models, and it has recently been reported that adeno-associated viruses (AAVs) can form tissue deposits after injection, which can lead to continued infection over time and alterations in the expression of the optogene ([@B307]). This problem may be avoided with single cell electroporation ([@B207]), but this limits the applications. Third, extreme stimulation can lead to an exhaustion of synaptic transmission ([@B222]). Therefore, it is important to modulate the expression and long-term, high frequency use of optogenes, and to use appropriate controls to detect any artifacts. Alternative approaches to optogenetics include the use of genetically targeted TrpA1 channels, which are a class of temperature-gated excitatory cation channels for depolarizing neurons ([@B399]; [@B101]; [@B170]). Work in *Drosophila* illustrates the power of TrpA1 manipulations, specifically in comparison to ChR2 optogenetics, as neurons expressing TrpA1 can show stronger and longer lasting electrophysiological effects ([@B331]).

*Drosophila* METHODS FOR STUDYING A-D DEVELOPMENTAL MECHANISMS
--------------------------------------------------------------

The "relative" simplicity of the *Drosophila* brain (hundreds of thousands of neurons) provides a high level of understanding about clonal lineages and connectivity among small, defined populations of neurons, even down to the individually identified single neuron level ([@B73]; [@B67]; [@B256]; [@B376]; [@B421]). Importantly, *Drosophila* genetics allows precise delivery of transgenic tools to these targeted neuronal populations using the GAL4/UAS bipartite system ([@B205]), and with the MARCM technique for clonal analysis down to the individually identified single neuron level ([@B240]; [@B303]). Our lab has utilized these techniques particularly to analyze individually identified neurons in the FXS disease model ([@B310]; [@B378]; [@B147]; [@B364]), as our best-defined *Drosophila* ASD model. More recently, *Drosophila* has gained an expansive catalog of highly selective neuronal GAL4 drivers, which utilize limited regulatory sequences for exquisitely limited expression ([@B202]; [@B263]). These new tools are providing the capacity to target defined neuronal circuits within the *Drosophila* brain at a never-before achieved level of resolution. The use of selective drivers for high-resolution morphological readouts of individual neurons, in combination with non-invasive methods of activity modulation, will greatly enhance our understanding of A-D mechanisms of synapse remodeling. We predict that the utilization of these new classes of neural drivers (in MB, projection neuron, fan body, ellipsoid body, retina, etc.), in combination with both optogenetic and alternative activity modulation techniques, will provide much better dissection of neuron class-specific A-D developmental mechanisms within the next few years. These studies will lead to a deeper understanding of ASD model disease states within precise maps of brain circuits, such as the MB ([@B314]; [@B321]) and antennal lobes ([@B377]), which will provide a foundation for deciphering the molecular genetic bases of these disease states and engineering effecting treatment strategies.

What are the current limitations on this use of the *Drosophila* system? For optogenetics, *Drosophila* requires an essential co-factor, all-trans retinal (ATR), for ChR2 activation ([@B354]; [@B11]), although this feature does provide a useful control. Moreover, fluorescent tags on optogenetic channels label targeted neurons to grant cell-autonomous morphological readouts of A-D modifications, but fail to illuminate their synaptic partners, although clever mapping techniques are being developed \[e.g., Genetic Reconstitution Across Synaptic Partners (GRASP); [@B128]\]. For example, the GRASP technique was recently used to synaptically link MB Kenyon cells with modulatory aminergic neurons ([@B319]). In a similar fashion, the CaLexA (calcium-dependent nuclear import of Lexa) neural tracing method may be useful for mapping synaptic partners ([@B269]). Alternatively, synaptic mapping studies may be more suited for larger subsets of neurons (broader GAL4 drivers), which are coupled to known targets and could then be assayed through standard immunohistochemistry. Further downstream, the use of immediate early neural genes, may help illuminate downstream effects of activity modulation (e.g., *Dhr38*; [@B138]). Importantly, use of the multiple methods now available for A-D manipulations during neurodevelopmental studies (e.g., ChR2, eNpHR, TrpA1, NaChBac) in the *Drosophila* FXS model can be used to directly test whether targeted brain circuitry is capable of responding appropriately to activity during defined developmental critical periods. Moreover, the capacity to genetically target subsets of neurons may allow suppression of downstream ASD-related phenotypes. For example, in the *Drosophila* FXS model, hypoinhibition (e.g., reduced GABAergic input) might be suppressed by increased depolarization of inhibitory interneurons using a GAD:Gal4 driver crossed to ChR2, and hyperexcitation (e.g., elevated mGluR activity) could similarly be suppressed by selectively hyperpolarizing specific groups of glutamatergic neurons with halorhodopsin. Such studies in the particularly well-characterized *Drosophila* FXS model could ultimately lead to new intervention strategies in FXS patients and, by extension, the treatment of other patient groups suffering ASDs.
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